GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

GSK has upgraded its longstanding alliance with ... Unperturbed, the two partners continued work on a second-generation COVID-19 shot that is in phase 2 testing, along with a seasonal influenza ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other most undervalued biotech stocks to invest in. On February 21, Jared Holz, Mizuho Securities ...